S. Morris

发表

L. Carey, S. Morris, 2007, Reviews in Endocrine and Metabolic Disorders.

Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study.

R. Kurzrock, Philippe Bédard, H. Burris, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation Of Afuresertib, An Oral Pan-AKT Inhibitor, In Patients With Langerhans Cell Histiocytosis

R. Arceci, E. Jacobsen, C. Rodríguez-Galindo, 2013 .

First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies

N. Agarwal, J. Schellens, R. Kurzrock, 2015, Clinical Cancer Research.

Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy‐induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials

W. Edenfield, S. Morris, Y. Pritchett, 2021, Cancer medicine.

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

T. Owonikoko, P. Roberts, J. Hamm, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway

G. Mills, H. Gabra, Rakesh Kumar, 2015, Oncotarget.

3 Afuresertib (GSK2110183), an oral AKT kinase inhibitor, in combination with carboplatin and paclitaxel in recurrent ovarian cancer

H. Gabra, L. Mileshkin, M. Hall, 2014 .

Trilaciclib (T) decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy plus atezolizumab

I. Bondarenko, L. Hart, D. Spigel, 2019, Annals of Oncology.

Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.

A. Tan, T. Pluard, M. Danso, 2019, The Lancet. Oncology.

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.

T. Owonikoko, P. Roberts, J. Hamm, 2019 .

EP1.12-06 New Treatment Option for ES-SCLC: Patient Characteristics and Use of an Atezolizumab Regimen in the Real-World Setting

A. Mansfield, T. Mekhail, F. Braiteh, 2019, Journal of Thoracic Oncology.

A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors

H. Burris, J. Infante, L. Siu, 2018, Investigational New Drugs.

Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.

M. Rebelatto, M. Borad, G. Abou-Alfa, 2017 .

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

K. Flaherty, R. Kurzrock, L. Hart, 2012, The Lancet. Oncology.

Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study

J. Subramanian, T. Owonikoko, L. Hart, 2020, Advances in Therapy.

A phase IIa study of afuresertib, an oral pan‐AKT inhibitor, in patients with Langerhans cell histiocytosis

R. Arceci, M. Cornfeld, E. Jacobsen, 2017, Pediatric Blood & Cancer.

Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212.

K. Flaherty, H. Burris, J. Infante, 2010 .

Dose-Finding Quantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies

Sabin Carme, Syed Babar, Cristian Salinas, 2015, The Journal of Nuclear Medicine.

Pharmacokinetic (PK)/pharmacodynamic (PD) analysis of escalating repeat doses of the AKT inhibitor GSK2141795 (GSK795) in patients (pts) with ovarian cancer.

R. Gunn, H. Gabra, R. Agarwal, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: A multicentre, randomised, double‐blind, placebo‐controlled Phase II trial

I. Bondarenko, L. Hart, J. Goldschmidt, 2020, International journal of cancer.

Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.

L. Carey, S. Morris, 2006, Oncology.

Effect of Casopitant, a Novel NK‐1 Receptor Antagonist, on the Pharmacokinetics and Pharmacodynamics of Steady‐State Warfarin

S. Murray, S. Morris, B. Johnson, 2010, Journal of clinical pharmacology.

PI3K Kinase Inhibitor GSK2126458 (GSK458): Clinical Activity in Select Patient (PT) Populations Defined by Predictive Markers (STUDY P3K112826)

N. Agarwal, J. Schellens, A. Tan, 2012 .

Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies.

C. Gwaltney, K. Dragnev, K. Skaltsa, 2021, Clinical lung cancer.

The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma.

Rakesh Kumar, Sung-Soo Yoon, S. Harrison, 2014, Blood.

Gene expression profiling in breast cancer

Lisa A Carey, L. Carey, S. Morris, 2007, Current opinion in oncology.

Phase I dose-escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795).

A. Tolcher, R. Kurzrock, T. Mays, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract CT091: Safety and pharmacodynamic activity of MEDI9197, a TLR 7/8 agonist, administered intratumorally in subjects with solid tumors

J. Zha, J. Grilley-Olson, D. Hong, 2017 .

Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC).

M. Kudo, A. Zhu, G. Abou-Alfa, 2016 .

A phase 1, first-time-in-human study of MEDI9197, a TLR7/8 agonist, administered intratumorally in subjects with a solid tumor cancer.

Jeffrey S. Miller, S. Soukharev, S. Morris, 2016 .

Myelopreservation and reduced use of supportive care with trilaciclib in patients with small cell lung cancer.

K. Dragnev, J. Goldschmidt, S. Morris, 2020 .

Phase I first-in-human study of the PI3 kinase inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors (study P3K112826).

J. Schellens, A. Tan, R. Kurzrock, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer

R. Hohl, S. Murray, S. Morris, 2011, Cancer Chemotherapy and Pharmacology.

OA03.08 Trilaciclib Reduces the Need for Growth Factors and Red Blood Cell Transfusions to Manage Chemotherapy-Induced Myelosuppression

W. Edenfield, S. Morris, Y. Pritchett, 2021 .

MO01.42 Myelopreservation with Trilaciclib Regardless of Risk of Chemotherapy-Induced Febrile Neutropenia and/or Anemia or Red Blood Cell Transfusions

S. Gurubhagavatula, S. Morris, Y. Pritchett, 2021 .